The White House said Friday it’s adding three Boehringer Ingelheim drugs to the TrumpRx self-pay platform — pricing Jentadueto/Jentadueto XR for Type 2 diabetes around $55 (vs. ~$525 list) and the COPD inhaler Striverdi Respimat around $35 (vs. ~$276 list). Clinically, the discounts could help some cash-pay and high-deductible patients avoid medication rationing — but the savings don’t apply to insurance or deductibles.

The move

• The White House added Jentadueto, Jentadueto XR (Type 2 diabetes), and Striverdi Respimat (COPD) to TrumpRx, a cash-pay discount platform launched in January as part of President Trump’s drug-pricing push.

• TrumpRx pricing starts around $55 for the diabetes drugs and ~$35 for Striverdi, per the White House.

• Boehringer Ingelheim becomes the ninth manufacturer participating in the platform.

Why it Matters for Care

• For patients paying cash (or effectively cash due to high deductibles), lower up-front prices may reduce delayed fills and adherence gaps for Type 2 diabetes and COPD therapies.

• Jentadueto has a generic that can run ~$25–$35 at the counter, per 46brooklyn’s Ben Link — meaning TrumpRx may be competitive but not always the lowest-cost option.

• Because TrumpRx discounts can’t be combined with insurance or credited to a deductible, clinicians and staff may need to triage: use TrumpRx when immediate out-of-pocket cost is the barrier, not when patients are trying to meet a deductible.

Between the Lines

• HHS official Chris Klomp said TrumpRx was never intended for people with insurance — positioning it as a targeted cash-pay tool rather than a systemwide price reform.

• The platform’s limited formulary (fewer than 60 drugs) and emphasis on brand-name products, some with cheaper generics, fuels criticism that it can duplicate prices available elsewhere (e.g., other discount sites).

• Political upside: visible, headline-friendly “list vs. TrumpRx” price gaps — even as real-world impact depends on awareness, eligibility, and whether generics/other discounts beat the posted price.

What to Watch

• Whether the White House/HHS releases utilization metrics (visits, fills, repeat use) — data it has so far declined to share.

• Formulary growth: additional manufacturers/drugs added, and whether higher-impact categories (including GLP-1s) expand beyond comparison-shopping interest.

• Patient awareness and behavior: KFF found about one-third of people who take Rx drugs had heard at least something about TrumpRx; 7% had visited it (16% among GLP-1 users).

Source: NBC News Health